Novo VP Weighs In on Approval of Lilly's Obesity Pill

By BloombergApr 1, 2026, 9:12 PM

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close."

More ways to discover

Browse Australia news Discover ASX signals Browse all ASX stocks Browse all ASX ETFs Explore Australia companies Find the right ASX index

Novo VP Weighs In on Approval of Lilly's Obesity Pill

More from Australia

David Jones will close 19 department stores

Winton Land names Kate Baguley CFO for 2027

BlinkLab shares rise after 20-person autism study

Anagenics to buy Bio-First for $50,000

West Coast Silver lifts silver resource by 20%

GCM signs 24-month thermal agreement with Jinshiyu

More ways to discover